PTBP1 and hepatitis C virus infection: We propose that the combination of a PTB suppressor with known anti‐HCV drugs might provide a new regimen for improved therapeutic efficacy in the treatment of hepatitis C and may provide the potential advantage of preventing or decreasing drug‐resistant mutations in virus.